JPRN-UMIN000001242已完成2 期
Phase II clinical trial of personalized peptide vaccination for decetaxel no indicated patients with hormone-refractory prostate cancer - Personalized peptide vaccination for hormone-refractory prostate cancer patients
Kurume University Research Center for Innovative Cancer Therapy, Clinical Research Division0 个研究点目标入组 55 人开始时间: 2008年7月10日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •The following patients must be excluded: 1) Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation). 2) Patients with multiple cancers 3) Patients with the past history of severe allergic reactions. 4) Patients who are not accept contraception during the 1st vaccination to 70 days after the last vaccination. 5) Patients with positive for hepatitis B or C virus. 6) Patients who are judged inappropriate for the clinical trial by doctors.
研究者
相似试验
已完成
2 期
Phase II clinical trial of personalized peptide vaccination in patients with advanced/metastatic urotherial cancer previously treated with M-VAC chemotherapyrotherial cancerJPRN-UMIN000001061Kurume University School of medicine, Department of Immunology20
已完成
2 期
Phase II clinical trial of personalized peptide vaccination for standard therapy failure patients with malignant glioma (glioblastoma)malignant glioma (glioblastoma)JPRN-UMIN000001243Department of Immunology, Kurume University School of medicine40
已完成
2 期
Phase II clinical trial of personalized peptide vaccination for standard chemotherapy failed scirrhous gastric cancer patientsScirrhous gastric cancerJPRN-UMIN000001883Kurume University Cancer Vaccine Center100
已完成
2 期
Phase II clinical trial of personalized peptide vaccination for standard therapy failed Biliary cancer(Cholangiocell carcinoma,Gallbladder cancer and Biliary tract cancer) patientsBiliary cancer (Cholangiocell carcinoma,Gallbladder cancer and Biliary tract cancer)JPRN-UMIN000001884Kurume University Cancer Vaccine Center100
已完成
2 期
Phase II clinical trial of personalized peptide vaccination for Colon cancer patientsColon cancerJPRN-UMIN000002987Kurume University Cancer Vaccine Center100